Development of experimental and early investigational drugs for the treatment of Ebola virus infections

Bibliography

• CDC.gov. Outbreaks Chronology: Ebola Virus Disease. 2014. Available from: http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html [Cited 15 February 2015]
   Google Scholar
• Rampling T, Ewer K, Bowyer G, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. N Engl J Med 2015:1–10 [Epub ahead of print]
   Google Scholar
• ClinicalTrials.gov. A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants. 2015. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02313077?term=NCT02313077 [Cited 8 May 2015]
   Google Scholar
• ClinicalTrials.gov. A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. 2015. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT02296983 [Cited 28 February 2015]
   Google Scholar
• Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999;179(Suppl 1):S18–23
   PubMed Web of Science ®Google Scholar
• Guimard Y, Bwaka MA, Colebunders R, et al. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999;179(Suppl 1):S268–73
   PubMedGoogle Scholar
• Clark DV, Jahrling PB, Lawler JV. Clinical management of filovirus-infected patients. Viruses 2012;4(9):1668–86
   PubMed Web of Science ®Google Scholar
• WHO.int. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease. 2014. Available from: http://apps.who.int/iris/bitstream/10665/135591/1/WHO_HIS_SDS_2014.8_eng.pdf?ua=1 [Cited 15 January 2015]
   Google Scholar
• Mayoclinic.org. Blood transfusion. 2015. Available from: http://www.mayoclinic.org/tests-procedures/blood-transfusion/basics/risks/PRC-20021256 [Cited 8 May 2015]
   Google Scholar
• Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014;371(25):2394–401
   PubMed Web of Science ®Google Scholar
• Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 2015;372(1):40–7
   PubMed Web of Science ®Google Scholar
• WHO.int. Ebola Situation Report - 6 May 2015. 2015. Available from: http://apps.who.int/ebola/en/current-situation/ebola-situation-report-6-may-2015 [Cited 8 May 2015]
   Google Scholar
• CDC.gov. 2014 Ebola Outbreak in West Africa - Outbreak Distribution Map. 2015. Available from: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/distribution-map.html#areas [Cited 15 February 2015]
   Google Scholar
• Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014;371(15):1418–25
   PubMed Web of Science ®Google Scholar
• Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009;2(1-2):12–17
   PubMed Web of Science ®Google Scholar
• Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol 2013;4:267
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003;188(11):1618–29
   PubMed Web of Science ®Google Scholar
• Stroher U, West E, Bugany H, et al. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 2001;75(22):11025–33
   PubMed Web of Science ®Google Scholar
• Wahl-Jensen V, Kurz SK, Hazelton PR, et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005;79(4):2413–19
   PubMed Web of Science ®Google Scholar
• Nkoghe D, Leroy EM, Toung-Mve M, Gonzalez JP. Cutaneous manifestations of filovirus infections. Int J Dermatol 2012;51(9):1037–43
   PubMed Web of Science ®Google Scholar
• CDC.gov. Ebola Virus Disease (EVD) Information for Clinicians in U.S. Healthcare Settings. 2015. Available from: http://www.cdc.gov/vhf/ebola/healthcare-us/preparing/clinicians.html [Cited 8 May 2015]
   Google Scholar
• Gunther S, Asper M, Roser C, et al. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Res 2004;63(3):209–15
   PubMed Web of Science ®Google Scholar
• Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. Lippincott Williams and Wilkins; Philadelphia, PA, USA: 2013
   Google Scholar
• Moons AH, Peters RJ, Cate H, et al. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 2002;88(4):627–31
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003;362(9400):1953–8
   PubMed Web of Science ®Google Scholar
• Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007;196(Suppl 2):S390–9
   PubMed Web of Science ®Google Scholar
• Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001;104(1):74–8
   PubMed Web of Science ®Google Scholar
• Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 2003;41(12):2147–53
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699–709
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11(7):786–90
   PubMed Web of Science ®Google Scholar
• Boudreau JE, Bridle BW, Stephenson KB, et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 2009;17(8):1465–72
   PubMed Web of Science ®Google Scholar
• Kash JC, Muhlberger E, Carter V, et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006;80(6):3009–20
   PubMed Web of Science ®Google Scholar
• Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007;3(1):e2
   PubMed Web of Science ®Google Scholar
• Johnson JE, Nasar F, Coleman JW, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007;360(1):36–49
   PubMed Web of Science ®Google Scholar
• Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 2012;6(3):e1567
   PubMed Web of Science ®Google Scholar
• Clarke DK, Nasar F, Chong S, et al. Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. J Virol 2014;88(12):6690–701
   PubMed Web of Science ®Google Scholar
• Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011;204(Suppl 3):S785–90
   PubMed Web of Science ®Google Scholar
• Lai L, Davey R, Beck A, et al. Emergency Postexposure Vaccination With Vesicular Stomatitis Virus-Vectored Ebola Vaccine After Needlestick. JAMA 2015;33:1249–55
   Google Scholar
• Haasnoot J, de Vries W, Geutjes EJ, et al. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 2007;3(6):e86
   PubMed Web of Science ®Google Scholar
• Hoenen T, Jung S, Herwig A, et al. Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology 2010;403(1):56–66
   PubMed Web of Science ®Google Scholar
• Hoenen T, Groseth A, Kolesnikova L, et al. Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol 2006;80(14):7260–4
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Volchkova VA, Chepurnov AA, et al. Characterization of the L gene and 5’ trailer region of Ebola virus. J Gen Virol 1999;80(Pt 2):355–62
   PubMedGoogle Scholar
• Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;375(9729):1896–905
   PubMed Web of Science ®Google Scholar
• Thi EP, Mire CE, Lee AC, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 2015;521:362–5
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802. 2014. Available from: http://clinicaltrials.gov/show/NCT02041715 [Cited 15 January 2015]
   Google Scholar
• Gao J, Yin L. Drug development for controlling Ebola epidemic - a race against time. Drug Discov Ther 2014;8(5):229–31
   PubMedGoogle Scholar
• Promedmail.org. EBOLA VIRUS DISEASE - WEST AFRICA (120): MSF, SIERRA LEONE, DRUG, PAHO, AID. 2014. Available from: http://www.promedmail.org/direct.php?id=2673098 [Cited 15 January 2015]
   Google Scholar
• Warren TK, Shurtleff AC, Bavari S. Advanced morpholino oligomers: a novel approach to antiviral therapy. Antiviral Res 2012;94(1):80–8
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006;2(1):e1
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 2009;53(5):2089–99
   PubMed Web of Science ®Google Scholar
• Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16(9):991–4
   PubMed Web of Science ®Google Scholar
• Heald AE, Iversen PL, Saoud JB, et al. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother 2014;58(11):6639–47
   PubMed Web of Science ®Google Scholar
• Qiu X, Kobinger GP. Antibody therapy for Ebola: is the tide turning around? Hum Vaccin Immunother 2014;10(4):964–7
   Web of Science ®Google Scholar
• Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007;3(1):e9
   PubMed Web of Science ®Google Scholar
• Gupta M, Mahanty S, Bray M, et al. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol 2001;75(10):4649–54
   PubMed Web of Science ®Google Scholar
• Gupta M, Mahanty S, Greer P, et al. Persistent infection with ebola virus under conditions of partial immunity. J Virol 2004;78(2):958–67
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011;17(9):1128–31
   PubMed Web of Science ®Google Scholar
• Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012;4(158):158ra46
   Web of Science ®Google Scholar
• Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 2012;109(13):5034–9
   PubMed Web of Science ®Google Scholar
• Marzi A, Yoshida R, Miyamoto H, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012;7(4):e36192
   PubMed Web of Science ®Google Scholar
• Qiu X, Alimonti JB, Melito PL, et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 2011;141(2):218–27
   PubMed Web of Science ®Google Scholar
• Qiu X, Fernando L, Melito PL, et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 2012;6(3):e1575
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012;4(138):138ra81
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000;287(5458):1664–6
   PubMed Web of Science ®Google Scholar
• Castilho A, Bohorova N, Grass J, et al. Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PLoS One 2011;6(10):e26040
   PubMedGoogle Scholar
• Zeitlin L, Pettitt J, Scully C, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci USA 2011;108(51):20690–4
   PubMed Web of Science ®Google Scholar
• Olinger GGJr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 2012;109(44):18030–5
   PubMed Web of Science ®Google Scholar
• Pettitt J, Zeitlin L, Kim do H, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 2013;5(199):199ra13
   Google Scholar
• Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014;514(7520):47–53
   PubMed Web of Science ®Google Scholar
• McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 2014;349:g5488
   PubMed Web of Science ®Google Scholar
• Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014;371:2402–9
   PubMed Web of Science ®Google Scholar
• Georges-Courbot MC, Sanchez A, Lu CY, et al. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg Infect Dis 1997;3(1):59–62
   PubMed Web of Science ®Google Scholar
• Qiu X, Alimonti JB, Melito PL, et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 2011;141(2):218–27
   PubMed Web of Science ®Google Scholar
• Whaley KJ, Hiatt A, Zeitlin L. Emerging antibody products and Nicotiana manufacturing. Hum Vaccin 2011;7(3):349–56
   PubMed Web of Science ®Google Scholar
• Kupferschmidt K, Cohen J. Infectious diseases. Ebola drug trials lurch ahead. Science 2015;347(6223):701–2
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection. 2015. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02363322 [Cited 18 March 2015]
   Google Scholar
• ClinicalTrials.gov. A Phase 1a Open-Label Study to Assess the Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers. 2015. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02389192 [Cited 18 March 2015]
   Google Scholar
• Aman MJ, Kinch MS, Warfield K, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009;83(3):245–51
   PubMed Web of Science ®Google Scholar
• Kinch MS, Yunus AS, Lear C, et al. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res 2009;1(1):87–98
   PubMedGoogle Scholar
• Warren TK, Warfield KL, Wells J, et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010;54(5):2152–9
   PubMed Web of Science ®Google Scholar
• Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013;5(190):190ra79
   PubMed Web of Science ®Google Scholar
• Madrid PB, Chopra S, Manger ID, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013;8(4):e60579
   PubMed Web of Science ®Google Scholar
• Gehring G, Rohrmann K, Atenchong N, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014;69(8):2123–31
   PubMed Web of Science ®Google Scholar
• Muhlberger E, Weik M, Volchkov VE, et al. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol 1999;73(3):2333–42
   PubMed Web of Science ®Google Scholar
• Beniac DR, Melito PL, Devarennes SL, et al. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS One 2012;7(1):e29608
   PubMed Web of Science ®Google Scholar
• Promedmail.org. EBOLA VIRUS DISEASE - ex AFRICA (06): SPAIN CASE, USA CASE, US CASE MEDEVACED. 2014. Available from: http://www.promedmail.org/direct.php?id=2837374 [Cited 15 January 2015]
   Google Scholar
• WHO.int. WHO Meeting of the Scientific and Technical Advisory Committee on Ebola Experimental Interventions – Briefing note. 2014. Available from: http://www.who.int/medicines/ebola-treatment/scientific_tech_meeting/en/# [Cited 15 January 2015]
   Google Scholar
• Promedmail.org. EBOLA VIRUS DISEASE - WEST AFRICA (180): SIERRA LEONE, LIBERIA, USA, DRUGS, GUINEA. 2014. Available from: http://www.promedmail.org/direct.php?id=2813292 [Cited 15 January 2015]
   Google Scholar
• Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009;82(2):A84–98
   PubMed Web of Science ®Google Scholar
• Coates JA, Cammack N, Jenkinson HJ, et al. (-)-2’-deoxy-3’-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992;36(4):733–9
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients. 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT01769170 [Cited 15 January 2015]
   Google Scholar
• ClinicalTrials.gov. Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection (CMX001 Adv). 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT02087306 [Cited 15 January 2015]
   Google Scholar
• Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. Jama 2001;285(9):1155–63
   PubMed Web of Science ®Google Scholar
• Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004;24(6):547–51
   PubMed Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007;51(9):3168–76
   PubMed Web of Science ®Google Scholar
• Morrey JD, Taro BS, Siddharthan V, et al. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 2008;80(3):377–9
   PubMed Web of Science ®Google Scholar
• Julander JG, Shafer K, Smee DF, et al. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 2009;53(1):202–9
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza (FAVOR). 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT01728753 [Cited 15 January 2015]
   Google Scholar
• Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005;49(3):981–6
   PubMed Web of Science ®Google Scholar
• Sangawa H, Komeno T, Nishikawa H, et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 2013;57(11):5202–8
   PubMed Web of Science ®Google Scholar
• Smither SJ, Eastaugh LS, Steward JA, et al. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014;104:153–5
   PubMed Web of Science ®Google Scholar
• Oestereich L, Ludtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014;105:17–21
   PubMed Web of Science ®Google Scholar
• Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014;508:402–5
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430. 2015. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02319772 [Cited 8 May 2015]
   Google Scholar
• Takahashi S, Metcalf CJ, Ferrari MJ, et al. Reduced vaccination and the risk of measles and other childhood infections post-Ebola. Science 2015;347(6227):1240–2
   PubMed Web of Science ®Google Scholar
• Maruyama T, Rodriguez LL, Jahrling PB, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999;73(7):6024–30
   PubMed Web of Science ®Google Scholar
• Bray M, Davis K, Geisbert T, et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998;178(3):651–61
   PubMed Web of Science ®Google Scholar
• Bowen ET, Lloyd G, Harris WJ, et al. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet 1977;1(8011):571–3
   PubMed Web of Science ®Google Scholar
• Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999;179(Suppl 1):S203–17
   PubMed Web of Science ®Google Scholar
• Baskerville A, Bowen ET, Platt GS, et al. The pathology of experimental Ebola virus infection in monkeys. J Pathol 1978;125(3):131–8
   PubMed Web of Science ®Google Scholar
• Peterson AT. Good and Bad News about Ebola. PLoS Negl Trop Dis 2015;9(3):e0003509
   Google Scholar
• CDC.gov. Chronology of Marburg Hemorrhagic Fever Outbreaks. 2014. Available from: http://www.cdc.gov/vhf/marburg/resources/outbreak-table.html [Cited 18 March 2015]
   Google Scholar
• Warfield KL, Bradfute SB, Wells J, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 2009;83(13):6404–15
   PubMed Web of Science ®Google Scholar
• Lofts LL, Wells JB, Bavari S, Warfield KL. Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process. J Virol 2011;85(8):3905–17
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, et al. Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J Virol 2014;88(21):12703–14
   PubMed Web of Science ®Google Scholar
• Chen G, Koellhoffer JF, Zak SE, et al. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS Chem Biol 2014;9(10):2263–73
   PubMed Web of Science ®Google Scholar